No Cover Image

Journal article 294 views 43 downloads

Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands

Kanch Sharma Orcid Logo, Sean James Fallon, Thomas Davis, Scott Ankrett, Greg Munro, Gary Christopher Orcid Logo, Elizabeth Coulthard

Psychopharmacology, Volume: 239, Issue: 2, Pages: 605 - 619

Swansea University Author: Gary Christopher Orcid Logo

  • 62607_VoR.pdf

    PDF | Version of Record

    This article is licensed under a Creative Commons Attribution 4.0 International License

    Download (1.23MB)

Check full text

DOI (Published version): 10.1007/s00213-021-06054-9

Abstract

IntroductionCaffeine is frequently consumed to boost goal-directed attention. These procognitive effects may occur due to the adenosine-mediated enhancement of monoamines, such as dopamine, after caffeine administration. As such, caffeine’s beneficial effects may be altered in conditions such as Par...

Full description

Published in: Psychopharmacology
ISSN: 0033-3158 1432-2072
Published: Springer Science and Business Media LLC 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa62607
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2023-02-23T13:41:24Z
last_indexed 2023-02-24T04:19:21Z
id cronfa62607
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2023-02-23T13:42:48.7421323</datestamp><bib-version>v2</bib-version><id>62607</id><entry>2023-02-08</entry><title>Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson&#x2019;s disease according to task demands</title><swanseaauthors><author><sid>8092562c67809dfda89f7bb8582874d3</sid><ORCID>0000-0002-7175-6644</ORCID><firstname>Gary</firstname><surname>Christopher</surname><name>Gary Christopher</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-02-08</date><deptcode>PHAC</deptcode><abstract>IntroductionCaffeine is frequently consumed to boost goal-directed attention. These procognitive effects may occur due to the adenosine-mediated enhancement of monoamines, such as dopamine, after caffeine administration. As such, caffeine&#x2019;s beneficial effects may be altered in conditions such as Parkinson&#x2019;s disease (PD). However, whether caffeine improves cognition, and at what cost, has not been experimentally established in patients with neurodegenerative disease.MethodsSingle-dose trials to probe cognitive effects of caffeine are often confounded by short-term caffeine abstinence which conflates caffeine&#x2019;s effects with treatment of withdrawal. Using a placebo controlled, blinded, randomised trial design, we assessed the effect of 100 mg of caffeine across well-established tasks (Choice reaction time, Stroop Task and Rapid Serial Visual Presentation Task; RSVP) that probe different aspects of attention in PD patients (n&#x2009;=&#x2009;24) and controls (n&#x2009;=&#x2009;44). Critically, participants withdrew from caffeine for a week prior to testing to eliminate the possibility that withdrawal reversal explained any cognitive benefit.ResultsCaffeine administration was found to reduce the overall number of errors in patients and controls on the Stroop (p&#x2009;=&#x2009;.018, &#x3B7;2p&#x2009;=&#x2009;.086) and Choice reaction time (p&#x2009;&lt;&#x2009;. 0001, &#x3B7;2p&#x2009;=&#x2009;.588) tasks, but there was no specific effect of caffeine on ignoring irrelevant information in the Stroop task. On the RSVP task, caffeine improved dual item accuracy (p&#x2009;=&#x2009;.037) but impaired single item accuracy (p&#x2009;=&#x2009;.044). Across all tasks, there was little evidence that caffeine has different effects in PD participants and controls.ConclusionWhen removing withdrawal effects as a factor, we demonstrate caffeine has beneficial effects on selective attention but is a double-edge sword for visual temporal attention and would need careful targeting to be clinically useful.</abstract><type>Journal Article</type><journal>Psychopharmacology</journal><volume>239</volume><journalNumber>2</journalNumber><paginationStart>605</paginationStart><paginationEnd>619</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0033-3158</issnPrint><issnElectronic>1432-2072</issnElectronic><keywords>Caffeine; Attention; Yerkes-Dodson; Withdrawal; Parkinson&#x2019;s disease</keywords><publishedDay>1</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-02-01</publishedDate><doi>10.1007/s00213-021-06054-9</doi><url/><notes/><college>COLLEGE NANME</college><department>Public Health</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>PHAC</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2023-02-23T13:42:48.7421323</lastEdited><Created>2023-02-08T10:27:16.1371001</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">School of Health and Social Care - Public Health</level></path><authors><author><firstname>Kanch</firstname><surname>Sharma</surname><orcid>0000-0003-3337-3527</orcid><order>1</order></author><author><firstname>Sean James</firstname><surname>Fallon</surname><order>2</order></author><author><firstname>Thomas</firstname><surname>Davis</surname><order>3</order></author><author><firstname>Scott</firstname><surname>Ankrett</surname><order>4</order></author><author><firstname>Greg</firstname><surname>Munro</surname><order>5</order></author><author><firstname>Gary</firstname><surname>Christopher</surname><orcid>0000-0002-7175-6644</orcid><order>6</order></author><author><firstname>Elizabeth</firstname><surname>Coulthard</surname><order>7</order></author></authors><documents><document><filename>62607__26667__dadc9c861afb4bfd818849a431895a12.pdf</filename><originalFilename>62607_VoR.pdf</originalFilename><uploaded>2023-02-23T13:41:52.4994491</uploaded><type>Output</type><contentLength>1288867</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This article is licensed under a Creative Commons Attribution 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2023-02-23T13:42:48.7421323 v2 62607 2023-02-08 Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands 8092562c67809dfda89f7bb8582874d3 0000-0002-7175-6644 Gary Christopher Gary Christopher true false 2023-02-08 PHAC IntroductionCaffeine is frequently consumed to boost goal-directed attention. These procognitive effects may occur due to the adenosine-mediated enhancement of monoamines, such as dopamine, after caffeine administration. As such, caffeine’s beneficial effects may be altered in conditions such as Parkinson’s disease (PD). However, whether caffeine improves cognition, and at what cost, has not been experimentally established in patients with neurodegenerative disease.MethodsSingle-dose trials to probe cognitive effects of caffeine are often confounded by short-term caffeine abstinence which conflates caffeine’s effects with treatment of withdrawal. Using a placebo controlled, blinded, randomised trial design, we assessed the effect of 100 mg of caffeine across well-established tasks (Choice reaction time, Stroop Task and Rapid Serial Visual Presentation Task; RSVP) that probe different aspects of attention in PD patients (n = 24) and controls (n = 44). Critically, participants withdrew from caffeine for a week prior to testing to eliminate the possibility that withdrawal reversal explained any cognitive benefit.ResultsCaffeine administration was found to reduce the overall number of errors in patients and controls on the Stroop (p = .018, η2p = .086) and Choice reaction time (p < . 0001, η2p = .588) tasks, but there was no specific effect of caffeine on ignoring irrelevant information in the Stroop task. On the RSVP task, caffeine improved dual item accuracy (p = .037) but impaired single item accuracy (p = .044). Across all tasks, there was little evidence that caffeine has different effects in PD participants and controls.ConclusionWhen removing withdrawal effects as a factor, we demonstrate caffeine has beneficial effects on selective attention but is a double-edge sword for visual temporal attention and would need careful targeting to be clinically useful. Journal Article Psychopharmacology 239 2 605 619 Springer Science and Business Media LLC 0033-3158 1432-2072 Caffeine; Attention; Yerkes-Dodson; Withdrawal; Parkinson’s disease 1 2 2022 2022-02-01 10.1007/s00213-021-06054-9 COLLEGE NANME Public Health COLLEGE CODE PHAC Swansea University 2023-02-23T13:42:48.7421323 2023-02-08T10:27:16.1371001 Faculty of Medicine, Health and Life Sciences School of Health and Social Care - Public Health Kanch Sharma 0000-0003-3337-3527 1 Sean James Fallon 2 Thomas Davis 3 Scott Ankrett 4 Greg Munro 5 Gary Christopher 0000-0002-7175-6644 6 Elizabeth Coulthard 7 62607__26667__dadc9c861afb4bfd818849a431895a12.pdf 62607_VoR.pdf 2023-02-23T13:41:52.4994491 Output 1288867 application/pdf Version of Record true This article is licensed under a Creative Commons Attribution 4.0 International License true eng http://creativecommons.org/licenses/by/4.0/
title Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands
spellingShingle Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands
Gary Christopher
title_short Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands
title_full Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands
title_fullStr Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands
title_full_unstemmed Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands
title_sort Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands
author_id_str_mv 8092562c67809dfda89f7bb8582874d3
author_id_fullname_str_mv 8092562c67809dfda89f7bb8582874d3_***_Gary Christopher
author Gary Christopher
author2 Kanch Sharma
Sean James Fallon
Thomas Davis
Scott Ankrett
Greg Munro
Gary Christopher
Elizabeth Coulthard
format Journal article
container_title Psychopharmacology
container_volume 239
container_issue 2
container_start_page 605
publishDate 2022
institution Swansea University
issn 0033-3158
1432-2072
doi_str_mv 10.1007/s00213-021-06054-9
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str School of Health and Social Care - Public Health{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}School of Health and Social Care - Public Health
document_store_str 1
active_str 0
description IntroductionCaffeine is frequently consumed to boost goal-directed attention. These procognitive effects may occur due to the adenosine-mediated enhancement of monoamines, such as dopamine, after caffeine administration. As such, caffeine’s beneficial effects may be altered in conditions such as Parkinson’s disease (PD). However, whether caffeine improves cognition, and at what cost, has not been experimentally established in patients with neurodegenerative disease.MethodsSingle-dose trials to probe cognitive effects of caffeine are often confounded by short-term caffeine abstinence which conflates caffeine’s effects with treatment of withdrawal. Using a placebo controlled, blinded, randomised trial design, we assessed the effect of 100 mg of caffeine across well-established tasks (Choice reaction time, Stroop Task and Rapid Serial Visual Presentation Task; RSVP) that probe different aspects of attention in PD patients (n = 24) and controls (n = 44). Critically, participants withdrew from caffeine for a week prior to testing to eliminate the possibility that withdrawal reversal explained any cognitive benefit.ResultsCaffeine administration was found to reduce the overall number of errors in patients and controls on the Stroop (p = .018, η2p = .086) and Choice reaction time (p < . 0001, η2p = .588) tasks, but there was no specific effect of caffeine on ignoring irrelevant information in the Stroop task. On the RSVP task, caffeine improved dual item accuracy (p = .037) but impaired single item accuracy (p = .044). Across all tasks, there was little evidence that caffeine has different effects in PD participants and controls.ConclusionWhen removing withdrawal effects as a factor, we demonstrate caffeine has beneficial effects on selective attention but is a double-edge sword for visual temporal attention and would need careful targeting to be clinically useful.
published_date 2022-02-01T04:22:21Z
_version_ 1763754473172238336
score 11.013148

Similar Items